Amylyx Pharmaceuticals, INC. (AMLX) — 8-K Filings

8-K Filings (15)

• Amylyx Files 8-K, Discloses New Info via Reg FD on March 24, 2026 — Mar 24, 2026
  Amylyx Pharmaceuticals, Inc. filed an 8-K on March 24, 2026, under Item 7.01 Regulation FD Disclosure, indicating they are publicly disclosing information that
• Amylyx Pharmaceuticals Files 8-K — Sep 10, 2025 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on September 10, 2025, reporting an entry into a material definitive agreement and financial statements/exhibits. The
• Amylyx Pharmaceuticals Files 8-K — Aug 27, 2025 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, to report other events. The filing does not contain specific details about the nature of these eve
• Amylyx Pharmaceuticals Files 8-K on Financials — Aug 7, 2025 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Amylyx Pharmaceuticals Files 8-K on Security Holder Votes — Jun 5, 2025 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on June 5, 2025, to report on the submission of matters to a vote of security holders. The filing does not contain spe
• Amylyx Pharmaceuticals Files 8-K — Jan 10, 2025 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on January 10, 2025, reporting the entry into a material definitive agreement and the filing of financial statements a
• Amylyx Pharmaceuticals Files 8-K Report — Dec 30, 2024 Risk: low
  On December 30, 2024, Amylyx Pharmaceuticals, Inc. filed an 8-K report. The filing indicates it is a current report pursuant to Section 13 or 15(d) of the Secur
• Amylyx Pharmaceuticals Files 8-K — Oct 17, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on October 17, 2024, to report other events. The filing does not contain specific details about the nature of these ev
• Amylyx Acquires Knopp Neurosciences, Expands ALS Pipeline — Jul 10, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. announced on July 9, 2024, the completion of its acquisition of 100% of the outstanding shares of privately held Knopp Neuroscience
• Amylyx Pharmaceuticals Files 8-K for Material Agreement — Jun 21, 2024 Risk: medium
  On June 21, 2024, Amylyx Pharmaceuticals, Inc. filed an 8-K to report the entry into a material definitive agreement. The filing does not disclose specific deta
• Amylyx Pharmaceuticals Files 8-K on Security Holder Vote Matters — Jun 6, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on June 6, 2024, to report on the submission of matters to a vote of its security holders. The filing does not disclos
• Cooper Companies to Acquire Amylyx Pharma for $2.8B — Apr 10, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. announced on April 10, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of The Cooper Companies
• Amylyx Pharmaceuticals Files 8-K on Exit/Disposal Activities — Apr 4, 2024 Risk: medium
  Amylyx Pharmaceuticals, Inc. filed an 8-K on April 4, 2024, reporting on events that occurred on April 3, 2024. The filing indicates costs associated with exit
• Amylyx Pharmaceuticals Appoints New Directors, Updates Executive Compensation — Mar 14, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. announced on March 14, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two ne
• Amylyx Pharmaceuticals Files 8-K — Mar 8, 2024 Risk: low
  Amylyx Pharmaceuticals, Inc. filed an 8-K on March 8, 2024, to report on other events and potentially financial statements and exhibits. The filing does not det

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX